Refine by
Biomarker Joint Research Articles & Analysis
26 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood ...
CD BioGlyco, a leading provider in the field of glycoproteomics, has recently updated its Glycoprotein Quantification Service. This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, ...
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI ...
Deep Lens, a digital healthcare company focused on revolutionizing the oncology clinical trial recruitment process through artificial intelligence solutions, today announced the launch of its Real Time Feasibility offering, a new HIPAA-compliant tool designed to identify eligible patients and select the most effective sites in the Deep Lens Unity Network for oncology clinical trials in real-time. ...
CD Genomics, a genomics services company, has become one of the top providers in genomic research, devoting to providing reliable services to pharmaceutical and biotech companies as well as academia and government agencies. CD Genomics provides a wide range of services such as genome sequencing, RNA sequencing, epigenomics sequencing, genotyping, as well as integrated portfolios of multiple ...
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides fast, efficient separations with superior resolution and reproducibility, faster, simpler method development, and greater instrument ...
Exosomes, small lipid bilayer-enclosed particles of endosomal origin, are a subset of extracellular vesicles (EVs) that are secreted by most cell types. They are spherical, bilayered proteolipids and show a diverse mixture of exosomal nucleic acids (mRNA and non-coding RNA), proteins, and lipids, among which exosomal proteins play a key role in the pathological process of various diseases. At ...
As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, ...
Thermo Fisher Scientific, the world leader in serving science, today announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating ...
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3?) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians ...
Merck, a leading science and technology company, today hosted a panel discussion on the occasion of the 72nd World Health Assembly in Geneva, Switzerland. The panel entitled,“Leaving no one behind: from philanthropy to sustainable health solutions. How can decentralized manufacturing be part of an integrated approach to tackling NTDs and advancing Universal Health Coverage?” included ...
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...